<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>06948060430181</udiDi>
    <basicUdiDi>B-06948060430181</basicUdiDi>
    <tradeName>BioHyalux</tradeName>
    <deviceName>Biohyalux®</deviceName>
    <manufacturerName>Bloomage Biotechnology Corp.,Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013641</manufacturerSrn>
    <authorisedRepresentativeName>Wellkang Ltd</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>XI-AR-000001836</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDD</legislation>
    <emdnCode>X0301</emdnCode>
    <emdnDescription>SUBSTANCES, COMBINATIONS OF SUBSTANCES, OR ITEMS WITHOUT AN INTENDED MEDICAL PURPOSE INTENDED TO BE USED FOR FACIAL OR OTHER DERMAL OR MUCOUS MEMBRANE FILLING BY SUBCUTANEOUS, SUBMUCOUS OR INTRADERMAL INJECTION OR OTHER INTRODUCTION, EXCLUDING THOSE FOR TATTOOING – RESORBABLE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>6948060430181</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-06-27T23:41:34.065Z</lastUpdated>
  </row>
  <row>
    <udiDi>06948060430167</udiDi>
    <basicUdiDi>69480604HX0006J7</basicUdiDi>
    <tradeName>Hyprojoint</tradeName>
    <deviceName>Hyprojoint</deviceName>
    <manufacturerName>Bloomage Biotechnology Corp.,Ltd.</manufacturerName>
    <manufacturerSrn>CN-MF-000013641</manufacturerSrn>
    <authorisedRepresentativeName>Wellkang Ltd</authorisedRepresentativeName>
    <authorisedRepresentativeSrn>XI-AR-000001836</authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>P900402</emdnCode>
    <emdnDescription>RESORBABLE FILLING AND RECONSTRUCTION DEVICES</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>/</reference>
    <placedOnMarketCountry>Poland</placedOnMarketCountry>
    <lastUpdated>2026-06-27T23:41:28.117Z</lastUpdated>
  </row>
</eudamedExport>